Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics

Objective: FCN-159 is a highly active mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) inhibitor in patients with advanced melanoma and neurofibromatosis type 1 (NF1). We report a population pharmacokinetic (PopPK) model-based analysis of FCN-159 and its application to inform dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Yan, Cui, Ailing, Qian, Lixuan, Li, Chao, Wu, Zhuli, Yang, Yuchen, Han, Pu, Huang, Xin, Diao, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899833/
https://www.ncbi.nlm.nih.gov/pubmed/36755948
http://dx.doi.org/10.3389/fphar.2023.1101991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899833/
https://www.ncbi.nlm.nih.gov/pubmed/36755948
http://dx.doi.org/10.3389/fphar.2023.1101991

Ejemplares similares